EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats

Maxime Kurtz iD, Virginie Fabrès, Renaud Dumont iD, Valérie Chetboul iD, Sabine Chahory, Vittorio Saponaro, Emilie Trehiou, Camille Poissonnier, Peggy Passavin, Coline Jondeau, Matthieu Bott, Thierry Buronfosse and 1 more

Journal of Veterinary Internal Medicine · 2023

DOI: 10.1111/jvim.16741 ↗

At a glance

Journal article in Journal of Veterinary Internal Medicine, 2023. Written by Maxime Kurtz and 12 co-authors. Institution: Ecole Nationale Vétérinaire d'Alfort - CHUVA, Service de Médecine Interne, Maisons-Alfort, France. Major MEDLINE topics: Cat Diseases, Renal Insufficiency, Chronic, Hyperaldosteronism, Hypertension. Cited 8 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: ECVIM-CA Clinical Studies Fund.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

In a previous study, telmisartan suppressed aldosterone secretion in healthy cats but not in cats with primary hyperaldosteronism (PHA). Hypotheses Telmisartan suppresses aldosterone secretion in middle-aged healthy cat and cats with diseases that may result in secondary hyperaldosteronism, but not in those with PHA. Animals Thirty-eight cats: 5 with PHA; 16 with chronic kidney disease (CKD), subclassified as hypertensive (CKD-H) or non-hypertensive (CKD-NH); 9 with hyperthyroidism (HTH); 2 with idiopathic systemic arterial hypertension (ISH); and 6 healthy middle-aged cats.

Methods

Prospective, cross-sectional study. Serum aldosterone concentration, potassium concentration, and systolic blood pressure were measured before and 1 and 1.5 hours after PO administration of 2 mg/kg of telmisartan. The aldosterone variation rate (AVR) was calculated for each cat.

Results

No significant difference in the minimum AVR was observed among groups (median [quartile 1 (Q1); quartile 3 (Q3)]: 25 [0; 30]; 5 [−27; −75]; 10 [−6; −95]; 53 [19; 86]; 29 [5; 78]) for PHA, CKD, HTH, ISH, and healthy cats, respectively (P = .05). Basal serum aldosterone concentration (pmol/L) was significantly higher in PHA cats (median [Q1; Q3]: 2914 [2789; 4600]) than in CKD-H cats (median [Q1; Q3]: 239 [189; 577], corrected P value = .003) and CKD-NH cats (median [Q1; Q3]: 353 [136; 1371], corrected P value = .004). Conclusions and Clinical Importance The oral telmisartan suppression test using a single dose of 2 mg/kg telmisartan did not discriminate cats with PHA from healthy middle-aged cats or cats with diseases that may result in secondary hyperaldosteronism.

Subjects

MeSH terms (MEDLINE)

Cat DiseasesRenal Insufficiency, ChronicHyperaldosteronismHypertensionCross-Sectional StudiesNephritisAldosteroneHypertension, RenalCatsTelmisartanAnimals

Author keywords

adrenaladrenal glandaldosteronecardiologycardiovascularendocrinologyhemodynamicshypertensionhypertrophic cardiomyopathyhypokalemiaretinopathy

Substances

TelmisartanAldosterone

Authors and institutions

  • Ecole Nationale Vétérinaire d'Alfort - CHUVA, Service de Médecine Interne, Maisons-Alfort, France.
  • Aquivet Clinique Veterinaire - Service de Médecine Interne, Eysines, France.
  • Centre Hospitalier Veterinaire Fregis, Arcueil, France.
  • École Nationale Vétérinaire d'Alfort - CHUVA, Unité de Cardiologie d'Alfort, Maisons-Alfort, France.
  • Ecole Nationale Vétérinaire d'Alfort - CHUVA, Unité d'Ophtalmologie, Maisons-Alfort, France.
  • VetAgro Sup - Service De Biologie Clinique, Marcy-l'Etoile, France.

ORCID profiles: Maxime Kurtz, Renaud Dumont, Valérie Chetboul, Ghita Benchekroun

Funding

  • ECVIM-CA Clinical Studies Fund

Cite

APA

Kurtz, M., Fabrès, V., Dumont, R., Chetboul, V., Chahory, S., Saponaro, V., Trehiou, E., Poissonnier, C., Passavin, P., Jondeau, C., Bott, M., Buronfosse, T., & Benchekroun, G. (2023). Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16741

Vancouver

Kurtz M, Fabrès V, Dumont R, Chetboul V, Chahory S, Saponaro V, et al. Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats. Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16741

BibTeX
@article{Kurtz2023,
  author = {Kurtz, Maxime and Fabrès, Virginie and Dumont, Renaud and Chetboul, Valérie and Chahory, Sabine and Saponaro, Vittorio and Trehiou, Emilie and Poissonnier, Camille and Passavin, Peggy and Jondeau, Coline and Bott, Matthieu and Buronfosse, Thierry and Benchekroun, Ghita},
  title = {Prospective evaluation of a telmisartan suppression test as a diagnostic tool for primary hyperaldosteronism in cats},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2023},
  doi = {10.1111/jvim.16741}
}
Start for free →